Thousands find weight loss relief on Zepbound. Now, they face a choice: Try a different medicine that may have adverse side effects or stop treatment.

GLP‑1 receptor agonists are widely recognized for aiding weight loss and controlling blood sugar, but access remains limited — especially for Medicare and Medicaid patients. That might change with a ...

Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Weight loss and diabetes drugs on the market often do not achieve long-term weight loss for patients. GLP-1 drugs target ...

Novo took the active ingredient of Ozempic, semaglutide, and rebranded it as Wegovy to be used specifically for weight loss.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those ...

Key Takeaways Patients and doctors are disagreeing about sleep apnea treatment Doctors favor the use of CPAP machines But patients with obesity would rather use Zepbound to ease their apnea MONDAY ...

Primary Source New England Journal of Medicine Source Reference: Aronne LJ, et al "Tirzepatide as compared with semaglutide for the treatment of obesity" N Engl J Med 2025; DOI: 10.1056/NEJMoa2416394.